References

1. Ramji, D.P.; Foka, P. CCAAT/enhancer-binding proteins: Structure, function and regulation. Biochem. J. 2002, 365, 561–575.
2. Nerlov, C. The C/EBP family of transcription factors: A paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 2007, 17, 318–324.
3. Vinson; C. R.; Sigler, P.B.; McKnight, S.L. Scissors-grip model for DNA recognition by a family of leucine zipper proteins. Science 1989, 246, 911–916.
4. Osada, S.; Yamamoto, H.; Nishihara, T.; Imagawa, M. DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family. J. Biologic. Chem. 1996, 271, 3891–3896.
5. Williams, S.C.; Baer, M.; Dillner, A.J.; Johnson, P.F. CRP2 (C/EBPβ) contains a bipartite regulatory domain that controls transcriptional activation, DNA binding and cell specificity. EMBO J. 1995, 14, 3170–3183.
6. Descombes, P.; Schibler, U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 1991, 67, 569–579.
7. Welm, A.L.; Timochenko, N.A.; Darlington, G.J. C/EBPα regulates generation of C/EBPβ isoforms through activation of specific proteolytic cleavage. Mol. Cell. Biol. 1999, 19, 1695–1704.
8. Yamanaka, R.; Kim, G.D.; Radomska, H.S.; Lekstrom-Himes, J.; Smith, L.T.; Antonson, P.; Tenen, D.G.; Xanthopoulos, K.G. CCAAT/enhancer binding protein ε is preferentially up-regulated during granulocyte differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. Proc. Natl. Acad. Sci. USA 1997, 94, 6462–6467.
9. Wang, N.D.; Finegold, M.J.; Bradley, A.; Ou, C.N.; Abdelsayed, S.V.; Wilde, M.D.; Taylor, L.R.; Wilson, D.R.; Darlington, G.J. Impaired energy homeostasis in C/EBPα knockout mice. Science 1995, 269, 1108–1112.
10. Lin, F.T.; Lane, M.D. Antisense CCAAT/enhancer-binding protein RNA suppresses coordinate gene expression and triglyceride accumulation during differentiation of 3T3-L1 preadipocytes. Genes Dev. 1992, 6, 533–544.
11. Freytag, S.O.; Paielli, D.L.; Gilbert, J.D. Ectopic expression of the CCAAT/enhancer-binding protein α promotes the adipogenic program in a variety of mouse fibroblastic cells. Genes Dev. 1994, 15, 1654–1663.
12. Tanaka, T.; Yoshida, N.; Kishimoto, T.; Akira, S. Defective adipocyte differentiation in mice lacking the C/EBPβ and/or C/EBPδ gene. EMBO J. 1997, 16, 7432–7443.
13. Scott, L.M.; Civin, C.I.; Rorth, P.; Friedman, A.D. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 1992, 80, 1725–1735.
14. Morosetti, R.; Park, D.J.; Chumakov, A.M.; Grillier, I.; Shiohara, M.; Gombart, A.F.; Nakamaki, T.; Weinberg, K.; Koeffler, H.P. A novel, myeloid transcription factor, C/EBPε, is upregulated during granulocytic, but not monocytic, differentiation. Blood 1997, 90, 2591–2600.
15. Natsuka, S.; Akira, S.; Nishio, Y.; Hashimoto, S.; Sugita, T.; Isshiki, H.; Kishimoto, T. Macrophage differentiation-specific expression of NF-IL6, transcription factor for IL-6. Blood 1992, 79, 460–466.
16. Flodby, P.; Barlow, C.; Kylefjord, H.; Ahrlund-Richter, L.; Xanthopoulos, K.G. Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein α. J. Biol. Chem. 1996, 271, 24753–24760.
17. Robinson, G.W.; Johnson, P.F.; Hennighausen, L.; Sterneck, E. The C/EBPβ transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland. Genes Dev. 1998, 12, 1907–1916.
18. Zhu, S.; Oh, H.S.; Shim, M.; Sterneck, E.; Johnson, P.F.; Smart, R.C. C/EBPβ modulates the early events of keratinocyte differentiation involving growth arrest and keratin 1 and keratin 10 expression. Mol. Cell. Biol. 1999, 19, 7181–7190.
19. Cortes-Canteli, M.; Pignatelli, M.; Santos; A.; Perez-Castillo, A. CCAAT/enhancer binding protein β plays a regulatory role in differentiation and apoptosis of neuroblastoma cells. J. Biol. Chem. 2002, 277, 5460–5467.
20. Chandrasekaran, C.; Gordon, J.I. Cell lineage-specific and differentiation dependent patterns of CCAAT/enhancer binding protein α in the gut epithelium of normal and transgenic mice. Proc. Natl. Acad. Sci. USA 1993, 90, 8871–8875.
21. Darlington, G.J.; Ross, S.E.; MacDougald, O.A. The role of C/EBP genes in adipocyte differentiation. J. Biol. Chem. 1988, 273, 30057–30060.
22. Taubenfeld, S.M.; Wiig, K.A.; Monti, B.; Dolan, B.; Pollonini, G.; Alberini, C.M. Fornix-dependent induction of hippocampal CCAAT enhancer-binding protein β and δ co-localizes with phosphorylated cAMP response element-binding protein and accompanies long-term memory consolidation. J. Neurosci. 2001, 21, 84–91.
23. Umek, R.M.; Friedman, A.D.; McKnight, S.L. CCAAT-enhancer binding protein: A component of a differentiation switch. Science 1991, 251, 288–292.
24. Wang, H.; Iakova, P.; Wilde, M.; Welm, A.; Goode, T.; Roesler, W.J.; Timchenko, N.A. C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol. Cell 2001, 8, 817–828.
25. Harris, T.E.; Albrecht, J.H.; Nakanishi, M.; Darlington, G.J. CCAAT/enhancer-binding protein-alpha cooperates with p21 to inhibit cyclin-dependent kinase-2 activity and induces growth arrest independent of DNA binding. J. Biol. Chem. 2001, 276, 29200–29209.
26. lomiany, B.A.; D’Arigo, K.L.; Kelly, M.M.; Kurtz, D.T. C/EBPalpha inhibits cell growth via direct repression of E2F-DP-mediated transcription. Mol. Cell. Biol. 2000, 20, 5986–5997.
27. Yoon, K.; Smart, R.C. C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. Mol. Cell Biol. 2004, 24, 10650–10660.
28. Calkhoven, C.F.; Bouwman, P.R.; Snippe, L.; Ab, G. Translation start site multiplicity of the CCAAT/enhancer binding protein alpha mRNA is dictated by a small 5’ open reading frame. Nucleic Acids Res. 1994, 22, 5540–5547.
29. Zhang, D.E.; Zhang, P.; Wang, N.D.; Hetherington, C.J.; Darlington, G.J.; Tenen, D.G. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc. Natl. Acad. Sci. USA 1997, 94, 569–574.
30. Zhang, P.; Iwasaki-Arai, J.; Iwasaki, H.; Fenyus, M.L.; Dayaram, T.; Owens, B.M.; Shigematsu, H.; Levantini, E.; Huettner, C.S.; Lekstrom-Himes, J.A.; et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity 2004, 21, 853–863.
31. Ye, M.; Zhang, H.; Amabile, G.; Yang, H.; Staber, P.B.; Zhang, P.; Levantini, E.; Alberich-Jordà, M.; Zhang, J.; Kawasaki, A.; et al. C/EBPa controls acquisition and maintenance of adult haematopoietic stem cell quiescence. Nat. Cell Biol. 2013, 15, 385–394.
32. Pabst, T.; Mueller, B.U.; Harakawa, N.; Schoch. C.; Haferlach, T.; Behre, G.; Hiddemann, W.; Zhang, D.E.; Tenen, D.G. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 2001, 7, 444–451.
33. Perrotti, D.; Cesi, V.; Trotta, R.; Guerzoni, C.; Santilli, G.; Campbell, K.; Iervolino, A.; Condorelli, F.; Gambacorti-Passerini, C.; Caligiuri, M.A.; et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat. Genet. 2002, 30, 48–58.
34. Rosenbauer, F.; Tenen, D.G. Transcription factors in myeloid development: Balancing differentiation with transformation. Nat. Rev. Immunol. 2007, 7, 105–117.
35. Zheng, R.; Friedman, A.D.; Levis, M.; Li, L.; Weir, E.G.; Small, D. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood 2004, 103, 1883–1890.
36. Lourenço, A.-R.; Coffer, P.J. A tumor suppressor role for C/EBPα in solid tumors: More than fat and blood. Oncogene 2017, 36, 5221–5230.
37. Tomizawa, M.; Watanabe, K.; Saisho, H.; Nakagawara, A.; Tagawa, M. Down-regulated expression of the CCAAT/enhancer binding protein alpha and beta genes in human hepatocellular carcinoma: A possible prognostic marker. Anticancer Res. 2003, 23, 351–354.
38. Tseng, H.H.; Hwang, Y.H.; Yeh, K.T.; Chang, J.G.; Chen, Y.L.; Yu, H.S. Reduced expression of C/EBP alpha protein in HCC is associated with advanced tumor stage and shortened patient survival. J. Cancer Res. Clin. Oncol. 2009, 135, 241–247.
39. Lu, G.D.; Ang, Y.H.; Zhou, J.; Tamilarasi, J.; Yan, B.; Lim, Y.C.; Srivastava, S.; Salto-Tellez, M.; Hui, K.M.; Shen, H.M. CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma. Hepatology 2015, 61, 965–978.
40. Gray, S.G.; Kytola, S.; Matsunaga, T.; Larsson, C.; Ekstrom, T.J. Comparative genomic hybridization reveals population-based genetic alterations in hepatoblastomas. Br. J. Cancer 2000, 83, 1020–1025.
41. Wang, G.L.; Iakova, P.; Wilde, M.; Awad, S.; Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity. Genes Dev. 2004, 18, 912–925.
42. Cast, A.; Valanejad, L.; Wright, M.; Nguyen, P.; Gupta, A.; Zhu, L.; Shin, S.; Timchenko, N. C/EBPα-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer. Hepatology 2018, 67, 1857–1871.
43. Wang, GL.; Shi, X.; Haefliger, S.; Jin, J.; Major, A.; Iakova, P.; Finegold, M.; Timchenko, N.A. Elimination of C/EBPα through the ubiquitin–proteasome system promotes the development of liver cancer in mice. J. Clin. Investig. 2010, 120, 2549–2562.
44. Jiang, Y.; Iakova, P.; Jin, J.; Sullivan, S.; Sharin, V.; Hong, I.-H.; Anakk, S.; Mayor, A.; Darlington, G.; Finegold, M.; et al. FXR inhibits gankyrin in mouse livers and prevents development of liver cancer. Hepatology 2013, 57, 1098–1106.
45. Valanejad, L.; Lewis, K.; Wright, M.; Jiang, Y.; D’Souza, A.; Karns, R.; Sheridan, R.; Gupta, A.; Bove, K.; Witte, D.; et al. FXR–gankyrin axis is involved in development of pediatric liver cancer. Carcinogenesis 2017, 38, 738–747.
46. Akira, S.; Isshiki, H.; Sugita, T.; Tanabe, O.; Kinoshita, S.; Nishio, Y.; Nakajima, T.; Hirano, T.; Kishimoto, T. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J. 1990, 9, 1897–1906.
47. Davydov, I.V.; Krammer, P.H.; Li-Weber, M. Nuclear factor-IL6 activates the human IL-4 promoter in T cells. J. Immunol. 1995, 155, 5273–5279.
48. van Dijk, T.B.; Baltus, B.; Raaijmakers, J.A.; Lammers, J.W.; Koenderman, L.; de Groot, R.P. A composite C/EBP binding site is essential for the activity of the promoter of the IL-3/IL-5/granulocyte-macrophage colony-stimulating factor receptor beta c gene. J. Immunol. 1999, 163, 2674–2680.
49. Greenwel, P.; Tanaka, S.; Penkov, D.; Zhang, W.; Olive, M.; Moll, J.; Vinson, C.; Di Liberto, M.; Ramirez, F. Tumor Necrosis Factor Alpha Inhibits Type I Collagen Synthesis through Repressive CCAAT/Enhancer-Binding Proteins. Mol. Cell. Biol. 2000, 20, 912–918.
50. Ruffell, D.; Mourkioti, F.; Gambardella, A.; Kirstetter, P.; Lopez, R.G.; Rosenthal, N.; Nerlov, C. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc. Natl. Acad. Sci. USA 2009, 106, 17475–17480.
51. Chen, X.; Liu, W.; Ambrosino, C.; Ruocco, M.R.; Poli, V.; Romani, L.; Quinto, I.; Barbieri, S.; Holmes, K.L.; Venuta, S.; et al. Impaired generation of bone marrow B lymphocytes in mice deficient in C/EBPbeta. Blood 1997, 90, 156–164.
52. Kovács, K.A.; Steinmann, M.; Magistretti, P.J.; Halfon, O.; Cardinaux, J.R. C/EBPbeta couples dopamine signalling to substance P precursor gene expression in striatal neurones. J. Neurochem. 2006, 98, 1390–1399.
53. Tanaka, T.; Uchiumi, T.; Hinoshita, E.; Inokuchi, A.; Toh, S.; Wada, M.; Takano, H.; Kohno, K.; Kuwano, M. The human multidrug resistance protein 2 gene: Functional characterization of the 5’-flanking region and expression in hepatic cells. Hepatology 1999, 30, 1507–1512.
54. Chen, G.K.; Sale, S.; Tan, T.; Ermoian, R.P.; Sikic, B.I. CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol. Pharmacol. 2004, 65, 906–916.
55. Sebastian, T.; Malik, R.; Thomas, S.; Sage, J.; Johnson, P.F. C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. EMBO J. 2005, 24, 3301–3312.
56. Campisi; J. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 2005, 120, 513–522.
57. Collado, M.; Blasco, M.A.; Serrano, M. Cellular senescence in cancer and aging. Cell 2007, 130, 223–233.
58. Adams, P.D. Healing and hurting: Molecular mechanisms, functions, and pathologies of cellular senescence. Mol. Cell 2009, 36, 2–14.
59. Sterneck, E.; Zhu, S.; Ramirez, A.; Jorcano, J.L.; Smart, R.C. Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis. Oncogene 2006, 25, 1272–1276.
60. Kowenz-Leutz, E.; Twamley, G.; Ansieau, S.; Leutz, A. Novel mechanism of C/EBP β (NF-M) transcriptional control: Activation through derepression. Genes Dev. 1994, 8, 2781–2791.
61. Mo, X.; Kowenz-Leutz, E.; Xu, H.; Leutz, A. Ras induces mediator complex exchange on C/EBP beta. Mol. Cell 2004, 13, 241–250.
62. Lee, S.; Shuman, J.D.; Guszczynski, T.; Sakchaisri, K.; Sebastian, T.; Copeland, T.D.; Miller, M.; Cohen, MS.; Taunton, J.; Smart, R.C.; et al. RSK-mediated phosphorylation in the C/EBP β leucine zipper regulates DNA binding, dimerization, and growth arrest activity. Mol. Cell Biol. 2010, 30, 2621–2635.
63. Basu, S.K.; Malik, R.; Huggins, C.J.; Lee, S.; Sebastian, T.; Sakchaisri, K.; Quiñones, O.A.; Alvord, W.G.; Johnson, P.F. 3’UTR elements inhibit Ras-induced C/EBPβ post-translational activation and senescence in tumour cells. EMBO J. 2011, 30, 3714–3728.
64. Basu, S.K.; Gonit, M.; Salotti, J.; Chen, J.; Bhat, A.; Gorospe, M.; Viollet, B.; Claffey, K.P.; Johnson, PF. A RAS-CaMKKβ-AMPKα2 pathway promotes senescence by licensing post-translational activation of C/EBPβ through a novel 3’UTR mechanism. Oncogene 2018, 37, 3528–3548.
65. Zahnow, C.A. CCAAT/enhancer-binding protein beta: Its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev. Mol. Med. 2009, 11, e12.
66. Gomis, R.R.; Alarcón, C.; Nadal, C.; Van Poznak, C.; Massagué, J. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 2006, 10, 203–214.
67. Haas, S.C.; Huber, R.; Gutsch, R.; Kandemir, J.D.; Cappello, C.; Krauter, J.; Duyster, J.; Ganser, A.; Brand, K. ITD- and FL-induced FLT3 signal transduction leads to increased C/EBPβ-LIP expression and LIP/LAP ratio by different signalling modules. Br. J. Haematol. 2010, 148, 777–790.
68. O’Rourke, J.P.; Newbound, G.C.; Hutt, J.A.; DeWille, J. CCAAT/enhancer-binding protein delta regulates mammary epithelial cell G0 growth arrest and apoptosis. Biol. Chem. 1999, 274, 16582–16589.
69. Dearth, L.R.; DeWille, J. Posttranscriptional and posttranslational regulation of C/EBP delta in G0 growth-arrested mammary epithelial cells. Biol. Chem. 2003, 278, 11246–11255.
70. Huang, A.M.; Montagna, C.; Sharan, S.; Ni, Y.; Ried, T.; Sterneck, E. Loss of CCAAT/enhancer binding protein delta promotes chromosomal instability. Oncogene 2004, 23, 1549–1557.
71. Balamurugan, K.; Sterneck, E. The many faces of C/EBPdelta and their relevance for inflammation and cancer. J. Biol. Sci. 2013, 9, 917–933.
72. Pawar, S.A.; Sarkar, T.; Balamurugan, K.; Sharan, S.; Wang, J.; Zhang, Y.; Dowdy, S.F.; Huang, A.M.; Sterneck, E. C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. Natl. Acad. Sci. USA 2010, 107, 9210–9215.
73. Umayahara, Y.; Ji, C.; Centrella, M.; Rotwein, P.; McCarthy, T.L. CCAAT/enhancer-binding protein delta activates insulin-like growth factor-I gene transcription in osteoblasts. Identification of a novel cyclic AMP signaling pathway in bone. Biol. Chem. 1997, 272, 1793–1800.
74. Fukuoka, T.; Kitami, Y.; Okura, T.; Hiwada, K. Transcriptional regulation of the platelet-derived growth factor alpha receptor gene via CCAAT/enhancer-binding protein-delta in vascular smooth muscle cells. Biol. Chem. 1999, 274, 25576–25582.
75. Cooper, C.; Henderson, A.; Artandi, S.; Avitahl, N.; Calame, K. Ig/EBP (C/EBPγ) is a transdominant negative inhibitor of C/EBP family transcriptional activators. Nucleic Acids Res. 1995, 23, 4371–4377.
76. Williamson, E.A.; Xu, H.N.; Gombart, A.F.; Verbeek, W.; Chumakov, A.M.; Friedman, A.D.; Koeffler, HP. Identification of transcriptional activation and repression domains in human CCAAT/enhancer-binding protein epsilon. Biol. Chem. 1998, 273, 14796–14804.
77. Chumakov, A.M.; Grillier, I.; Chumakova, E.; Chih, D.; Slater, J.; Koeffler, H.P. Cloning of the novel human myeloid-cell-specific C/EBP-epsilon transcription factor. Cell. Biol. 1997, 17, 1375–1386.
78. Bedi, R.; Du, J.; Sharma, A.K.; Gomes, I.; Ackerman, S.J. Human. C/EBP-epsilon activator and repressor isoforms differentially reprogram myeloid lineage commitment and differentiation. Blood 2009, 113, 317–327.
79. Oyadomari, S.; Mori, M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004, 11, 381–389.
80. Huber, A.L.; Lebeau, J.; Guillaumot, P.; Petrilli, V.; Malek, M.; Chilloux, J.; Fauvet, F.; Payen, L.; Kfoury, A.; Renno, T.; et al. p58(IPK)-mediated attenuation of the proapoptotic PERK-CHOP pathway allows malignant progression upon low glucose. Cell 2013, 49, 1049–1059.
81. Nakagawa, H.; Umemura, A.; Taniguchi, K.,; Font-Burgada, J.; Dhar, D.; Ogata, H.; Zhong, Z.; Valasek, M.A.; Seki, E.; Hidalgo, J. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 2014, 26, 331–343.
82. van Galen, P.; Kreso, A.; Mbong, N.; Kent, D.G.; Fitzmaurice, T.; Chambers, J.E.; Xie, S.; Laurenti, E.; Hermans, K.; Eppert, K.; et al. The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress. Nature 2014, 510, 268–272.
83. Patil, N.; Ahmed Kabeer Rasheed, S.; Abba, M.; Hendrik Leupold, J.; Schwarzbach, M.; Allgayer, H. A mechanistic study on the metastasis inducing function of FUS-CHOP fusion protein in liposarcoma. J. Cancer 2014, 134, 2808–2819.